Board of Directors
Donald Parfet has served as the chairman of our board of directors since our inception in 2003. Since 2001, Mr. Parfet has served as the managing director of the Apjohn Group, LLC, a business development group. Additionally, since 2003, he has served as a general partner of Apjohn Ventures Fund, a venture capital firm. Prior to founding the Apjohn Group, Mr. Parfet served as the Senior Vice President at Pharmacia & Upjohn. Mr. Parfet serves on the boards of directors of Kelly Services, Inc., Rockwell Automation, Inc. and Masco Corporation, and serves as a director or trustee of a number of business, civic and charitable organizations. Mr. Parfet holds a BA from the University of Arizona and an MBA from the University of Michigan.
Dr. Andrew Allen has served as the Chief Executive Officer and President of Gritstone Oncology, Inc., an immunotherapy company that he co-founded, since August 2015. From April 2009 to August 15, Dr. Allen served as he Executive Vice President of Clinical and Pre-Clinical Development and Chief Medical Officer of Clovis Oncology, Inc., a biopharmaceutical company that he co-founded. Prior to co-founding Clovis, he served in the same role at Pharmion Corporation, a pharmaceutical company, beginning in 2006. From 2004 to 2006, Dr. Allen served as Vice President of BioPharma Development and Head of Oncology Therapeutic Unit for Chiron Corporation, a biotechnology company. Prior to that, Dr. Allen served as global project head in Abbott Laboratories' oncology franchise, and he progressed through positions of increasing responsibility at the management consulting firm McKinsey & Company, with a focus on oncology strategy. Dr. Allen currently serves on the board of directors of Gritstone Oncology, Revitope Inc., Epizyme and Cell Design Labs, and previously served on the board of directors for Nodality, Inc. Dr. Allen qualified in medicine at Oxford University and earned his PhD from the Imperial College of Science, Technology and Medicine in London. Dr. Allen also obtained post-graduate internal medicine qualification as a Member of the Royal College of Physicians.
Jeffrey Cooper has served as an independent consultant for life science companies since January 2014. Previously, Mr. Cooper served at KaloBios Pharmaceuticals, Inc., a biotechnology company, as a senior advisor from November 2013 until December 2013, and as the Chief Financial Officer from July 2012 until October 2013. Prior to joining KaloBios, Mr. Cooper served in positions of increasing responsibility at BioMarin Pharmaceutical, Inc., a pharmaceutical company, beginning as Vice President, Controller, to his most recent position as Senior Vice President and Chief Financial Officer from 2007 to May 2012. He has also served as Vice President of Finance at Matrix Pharmaceutical, Inc. and held numerous finance-related positions within the heath care and pharmaceutical industries, including Corporate Controller at Foundation Health Systems and Director of Business Analysis at Syntex Corporation. He previously served on the board of directors of Tobira Therapeutics, Inc. until it was acquired by Allergan plc in November 2016. Mr. Cooper received a BA from the University of California, Los Angeles and an MBA from Santa Clara University. He is a Certified Public Accountant, under inactive status, in the State of California.
Dr. Daniel Estes has served as a member of our board of directors since April 2017. Dr. Estes is a Partner at Frazier Healthcare Partners and serves on the boards of Semnur Pharmaceuticals, Outpost Medicine, Cirius Therapeutics, and Arcutis. Prior to joining Frazier, Dr. Estes was a management consultant with McKinsey & Company’s healthcare practice, where he led teams that advised global pharmaceutical and biotechnology companies on R&D strategy and business development strategy. Dr. Estes received his Ph.D. in Biomedical Engineering from the University of Michigan, where his doctoral research focused on studying the roles of potassium ion channels on human T cells in human autoimmune diseases. He also holds a B.S. in Electrical Engineering from Stanford University.
Dr. Nick Glover is an accomplished life sciences professional, with extensive strategic, financial and operational experience in the biotechnology sector, evidenced by demonstrable value creation and successful outcomes. Previously, Dr. Glover served as the President and Chief Executive Officer at YM BioSciences Inc., a publically traded oncology drug development company acquired by Gilead Sciences Inc. in February 2013. YM’s lead drug candidate, momelotinib, was an orally administered JAK inhibitor being developed for the treatment of myelofibrosis and other hematological disorders. Prior to that, Dr. Glover served as the President and Chief Executive Officer of Viventia Bio Inc., a publically traded biopharmaceutical company focused on the development of monoclonal antibody technologies. Dr. Glover also previously served as an investment manager for MDS Capital, a life sciences venture capital firm. He currently serves on the board of directors of MEI Pharma Inc., a company developing novel therapies for hematology and oncology. Dr. Glover holds a BSc (Hons) in chemistry from the University of East Anglia, a MSc in chemistry from the University of British Columbia and a PhD in chemistry from Simon Fraser University.
Mr. Tran Nguyen has served as the Chief Financial Officer of Prothena Corporation plc, a biotechnology company, since March 2013. Previously, Mr. Nguyen served at Somaxon Pharmaceuticals, Inc. as Vice President, Chief Financial Officer from 2010 to 2011 and Senior Vice President, Chief Financial Officer from 2011 until its sale in 2013. He has also served as Vice President, Chief Financial Officer at Metabasis Therapeutics, Inc., as a Vice President in the Healthcare Investment Banking group at Citi Global Markets, Inc. and in various capacities as a health care investment banker at Lehman Brothers, Inc. Mr. Nguyen received a BA from Claremont McKenna College and an MBA from the Anderson School of Management at the University of California, Los Angeles.
Dr. Nicole Onetto has served as a member of our Board of Directors since May 2015. Dr. Onetto has served as an independent consultant in oncology drug development and translational research since June 2016. Dr. Onetto previously served as the Deputy Director and Chief Scientific Officer at the Ontario Institute for Cancer Research from November 2009 to June 2016. Dr. Onetto also previously served as the Senior Vice President and Chief Medical Officer at ZymoGenetics, Inc., a biotechnology company, from September 2005 until November 2009. Dr. Onetto also served as the Executive Vice President and Chief Medical Officer of OSI Pharmaceuticals, Inc., the Senior Vice President, Medical Affairs of Gilead Sciences, Inc. and as the Vice President, Medical Affairs of NeXstar. Dr. Onetto has also held positions at Bristol-Myers Squibb, Immunex and Hoechst Canada, Inc. Dr. Onetto previously served on the Board of Directors of ImmunoGen and YM BioSciences Inc. and she currently is on the boardof Basilea and NBE therapeutics. Dr. Onetto received a B.Sc. from the University of Paris, an M.Sc. in Pharmacology from the University of Montreal and an M.D. as well as an Oncology-Hematology certification from the University of Paris.
Robert Pelzer has served as a member of our board of directors since May 2015. From September 2008 to March 2013, Mr. Pelzer served as the President of Novartis Corporation, a pharmaceutical company. From 2002 to 2008, Mr. Pelzer served as General Counsel at Novartis Pharma AG. Prior to 2002, Mr. Pelzer held various positions at DuPont, including serving as General Counsel and Senior Vice President at DuPont Pharmaceuticals from 1998 to 2001. Mr. Pelzer currently serves on the board of directors of Aquinox Pharmaceuticals, Inc. and previously served on the board of directors of Idenix Pharmaceuticals, Inc. Mr. Pelzer holds a BA and an LL.B. from the University of Alberta.